Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Join | Sign in
Home>Videos>This Video
  Videos

Return

Bio-Rad Droplet Digital™ PCR and Organ Transplant Rejection
Bio-Rad Laboratories

Researchers at Chronix Biomedical applied Bio-Rad's ddPCR™ technology to quantify graft-derived cell-free DNA (cfDNA) in recent liver transplant patients and in stable patients who had undergone a transplant procedure more than six months earlier. ddPCR technology allowed Chronix to develop a fast and cost-effective laboratory test to detect cfDNA released into the blood stream by dying cells from the transplanted organ.

Sequencing methods typically require batch sampling, but using ddPCR assays, researchers are able to run single samples. Additionally, this method reduces test time from three days or more to one day, and reduces costs by 90 percent. The study authors were able to address the need for donor DNA by preselecting single-nucleotide polymorphisms (SNPs) that ensure enough heterogeneity between donor and recipient. The new blood test can also deliver results up to several days earlier than the conventional aspartate aminotransferase (AST) and bilirubin tests for liver transplantation rejection, with the potential for an immediate positive impact on patient care.

Chronix Biomedical is a molecular diagnostics company developing blood tests primarily for cancer, including companion diagnostics and tests for detecting minimal residual disease. Chronix is preparing to offer its pioneering tests through its own laboratories under CLIA certification in North America and the CE mark in Europe. The Company's initial product is a test to be used by cancer treatment centers and oncologists in the treatment of breast cancer patients. Chronix is privately held with headquarters in San Jose, California, and laboratories in Göttingen, Germany and Brookings, South Dakota.

The Droplet Digital PCR system enables the quantification of target DNA with unrivaled precision by partitioning samples into 20,000 nanoliter-sized droplets. After PCR on a thermal cycler, PCR-positive and PCR-negative droplets are counted to provide absolute quantification of the target DNA. The QX200™ system, Bio-Rad's second-generation digital PCR system, provides absolute quantification of target DNA or RNA molecules using EvaGreen or TaqMan hydrolysis probes, yielding unmatched sensitivity and precision for a wide variety of applications.

Request more information
Company product page


Access to this article and other content is for registered users.

Join the Technology Networks Community

  • Access to the latest scientific news, products and research through Technology Networks
  • Upload and share your posters on ePosters
  • View a library of 1,800+ scientific and medical posters
  • A library of 3,000+ scientific videos on LabTube


Sign In



Forgotten your details? Click Here
If you already have an account with Technology Networks, please use your existing login details. If you do not yet have an account please join here.

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Imaging Immunity
Noninvasive imaging of immune system detects tumors, could monitor therapeutic response.
DNA Abnormalities Found in Children with Chronic Kidney Disease
Routine genetic screening of children with CKD could lead to earlier, more precise diagnoses.
New Technology For Early Detection Of Stomach Cancer
The innovative method identifies persons at risk for developing stomach cancer and for detecting tumors at an earlier stage.
Potential For Prediction Of Progression For Early Form Of Breast Cancer
Scientists in Manchester have identified a way to potentially predict which patients with an early form of breast cancer will experience disease progression.
Tumor-Only Genetic Sequencing May Misguide Cancer Treatment in Nearly Half of All Patients
Johns Hopkins scientists say the genetic code of tumors must be compared to patients’ noncancer genome to get a true picture.
Tumor DNA in Blood Reveals Lymphoma Progression
Using an advanced genetic test, researchers were able to detect diffuse large B-cell lymphoma (DLBCL) in blood serum before it could be seen on CT scans.
Breath Test For Detecting Head And Neck Cancer
A portable device can detect the presence of certain types of cancer in people's breath.
Likely Genetic Source Of Muscle Weakness Found
Simple genetic test by TGen reveals likely causes of disease, after other extensive testing failed; one child’s case produces discovery.
$1 Test Outperforms PSA Screening for Prostate Cancer
Dr. Qun "Treen" Huo of UCF's NanoScience Technology Center has developed a prostate cancer test using gold nanoparticles. Pilot studies found it to be more accurate than the standard PSA test.
Using Sound Waves To Detect Rare Cancer Cells
Acoustic device can rapidly isolate circulating tumor cells from patient blood samples.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters